Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Trial of Caloric Restriction and Activity to Reduce Chemoresistance in B-cell Acute Lymphoblastic Leukemia

NCT05082519 is registered in ClinicalTrials.gov with Etan Orgel as lead sponsor.

NCT NCT05082519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05082519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Trial of Caloric Restriction and Activity to Reduce Chemoresistance in B-cell Acute Lymphoblastic Leukemia
Lead sponsor
Etan Orgel
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2022
Completion date
August 15, 2032
Enrollment
240 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, obesity